News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma

Al's Comment:

 Great news!  This is one of my favorite experimental treatments.  Fast track designation will speed up the approval process!

 


Posted on: 12/26/2017

DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740